Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on October 16, 2018, reporting events occurring on October 16 and October 17, 2018. The filing details a registered direct offering of common stock and warrants to institutional investors.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $7.5 million.
- Net Proceeds: Approximately $6.9 million after deducting fees and expenses.
- Securities Issued: 5,769,231 shares of common stock and warrants exercisable for an equal number of shares.
- Offering Price: $1.30 per unit (one share plus one warrant).
- Warrant Terms: Exercise price of $1.67 per share; exercisable after six months; expire five years from the initial exercise date.
- Placement Agent Fees: H.C. Wainwright & Co., LLC to receive up to 6% of gross proceeds plus $30,000 in non-accountable expenses.
- Agent Warrants: 346,154 warrants issued to the placement agent at an exercise price of $1.625 per share.
Material Changes
The filing reports the entry into a Material Definitive Agreement for a capital raise. This represents a significant change in the company's capital structure and liquidity position, increasing cash reserves by approximately $6.9 million upon closing. The filing does not provide comparative financial data (revenue, profit, or margins) as it is a current report regarding a specific transaction rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
The Offering is expected to close on or about October 19, 2018, subject to customary closing conditions. The proceeds are intended to fund the company's operations, though specific allocation details are not provided in this text. The filing notes that the warrants are subject to adjustment for stock splits or similar recapitalization transactions. No specific risks or contingencies beyond standard closing conditions are detailed in the provided text.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $6.9 million net proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for ownership limitations and specific covenants.
- Confirm the dilution impact of the 5,769,231 new shares and the potential future dilution from the warrants.
- Check subsequent filings for the use of proceeds and any changes in the company's cash position.